NCT03898180 · Interventional trial
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
Overall registry status Completed
Phase 3
Conditions Urothelial Carcinoma
Delaware Valley sites
- Thomas Jefferson University Hospital ( Site 0051) · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory